146 related articles for article (PubMed ID: 26522767)
21. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
22. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
23. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Go RS
Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
[No Abstract] [Full Text] [Related]
24. The First Case Report of
Xie H; Zhao Z; Zeng D
Ann Lab Med; 2023 May; 43(3):295-298. PubMed ID: 36544342
[No Abstract] [Full Text] [Related]
25. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
26. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Lierman E; Selleslag D; Smits S; Billiet J; Vandenberghe P
Blood; 2012 Aug; 120(7):1529-31. PubMed ID: 22899477
[No Abstract] [Full Text] [Related]
28. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
[TBL] [Abstract][Full Text] [Related]
29. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of
Zhang L; Zhu X; Qu W; Lu Y; Feng Z; Zhao L
Haematologica; 2023 Dec; 108(12):3506-3510. PubMed ID: 37102606
[No Abstract] [Full Text] [Related]
30. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
[TBL] [Abstract][Full Text] [Related]
31. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case.
Heiss S; Erdel M; Gunsilius E; Nachbaur D; Tzankov A
Hum Pathol; 2005 Oct; 36(10):1148-51. PubMed ID: 16226118
[TBL] [Abstract][Full Text] [Related]
33. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
34. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion.
Lane SW; Fairbairn DJ; McCarthy C; Nandini A; Perry-Keene J; Kennedy GA
Br J Haematol; 2008 Aug; 142(4):503. PubMed ID: 18537978
[No Abstract] [Full Text] [Related]
35. Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous
Rizzuto G; Leoncin M; Imbergamo S; Taurino D; Mico MC; Tosi M; Michelato A; Buklijas K; Spinelli O; Lussana F; Lessi F; Pizzi M; Bonaldi L; Binotto G; Rambaldi A; Gurrieri C
Clin Case Rep; 2022 Jan; 10(1):e05212. PubMed ID: 35028141
[TBL] [Abstract][Full Text] [Related]
36. Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature.
Post GR; Holloman D; Christiansen L; Smith J; Stuart R; Lazarchick J
Leuk Res; 2010 Nov; 34(11):1543-4. PubMed ID: 20541805
[No Abstract] [Full Text] [Related]
37. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Bain BJ; Ahmad S
Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
[TBL] [Abstract][Full Text] [Related]
38. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
[TBL] [Abstract][Full Text] [Related]
40. RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
Such E; Liquori A; Mora E; Marco-Ayala J; Avetisyan G; Regadera A; Ibañez F; Panadero J; Senent L; Llop M; Díaz A; Vicente A; Luna I; Ibáñez M; Barragán E; Sanz MA; Sanz G; Communidad Valenciana ; Cervera J
Acta Haematol; 2019; 142(2):92-97. PubMed ID: 31085913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
